Investmed Holdings Pty Limited has acquired 25% of Presmed Australia
Advanced Health Limited has sold 25% of its shares in Presmed Australia to Investmed Holdings Pty Limited.
Presmed Australia is the owner and operator of four day hospitals in Australia. Founded in 1997, it is one of the leading healthcare companies in Australia that specializes in the establishment and management of surgical day hospitals.
Investmed Holdings is an investment company formed by the management of Presmed Australia.
Advanced Health establishes, invests in and manages day hospitals. Its facilities are modern, compact and equipped to render same-day surgical procedures.
Oaklins’ team in South Africa acted as designated advisor to Advanced Health Limited.
Talk to the deal team
Annerie Britz
Oaklins South Africa
Jean De Wet
Oaklins South Africa
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more